Zacks Investment Research·Aug 20, 2026
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock RisesAUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Aurinia Pharmaceuticals has executed a remarkable operational turnaround, with revenue accelerating 18.9% year-over-year to $83.2M in 2026Q2 and operating margin expanding from -21.3% in 2024Q1 to 55.7% in 2026Q2, driven by scale benefits and disciplined SG&A ...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.28+16.7% vs $0.24 | $83M+3.4% vs $80M |
Q2 2026 May 7, 2026 | $0.25+38.9% vs $0.18 | $78M+0.9% vs $77M |
Q1 2026 Feb 26, 2026 | $0.26+23.8% vs $0.21 | $77M+3.2% vs $75M |
Q4 2025 Nov 4, 2025 | $0.23+43.8% vs $0.16 | $73M+8.5% vs $68M |
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
Benchmark AUPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aurinia Pharmaceuticals Inc. (AUPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.67 | $2.14B | 8.05 | 20.38% | 101.47% | 59.91% | — | |
| $298.50 | $5.98B | 48.69 | 60.4% | 67.88% | 20.06% | — | |
| $77.91 | $1.77B | 23.47 | 43.78% | 10.82% | 19.19% | — | |
| $300.65 | $8.38B | -22.30 | -100% | — | -34.15% | — | |
| $117.51 | $12.61B | 143.30 | 12.79% | 6.61% | 8.37% | — | |
| $50.72 | $101.62B | 13.66 | 4.11% | 14.52% | 24.99% | — |
Aurinia Pharmaceuticals Inc. (AUPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Aurinia Pharmaceuticals Inc. (AUPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 4, 2026·SEC
May 11, 2026·SEC
Get notified when AUPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aurinia Pharmaceuticals Inc. (AUPH) stock FAQ — growth, dividends, profitability & financials explained
Aurinia Pharmaceuticals Inc. (AUPH) reported $311.5M in revenue for fiscal year 2025. This represents a 39773% increase from $0.8M in 1998.
Aurinia Pharmaceuticals Inc. (AUPH) grew revenue by 20.4% over the past year. This is strong growth.
Yes, Aurinia Pharmaceuticals Inc. (AUPH) is profitable, generating $314.1M in net income for fiscal year 2025 (101.5% net margin).
Aurinia Pharmaceuticals Inc. (AUPH) has a return on equity (ROE) of 59.9%. This is excellent, indicating efficient use of shareholder capital.
Aurinia Pharmaceuticals Inc. (AUPH) generated $206.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
